TOP HEADLINES

Featured Story

  • Illumina taps former Google exec to lead liquid biopsy spinoff

    Illumina said last month that it was "actively recruiting" a CEO for its new liquid biopsy spinoff, Grail, looking for someone with an extensive tech background. Now the company has tapped a former Google exec for the role, charging its new leader with helping Grail develop a screening test for the early detection of cancer.

In tuck-in deal, Stryker to nab neurology devices made by Valeant on behalf of J&J

Stryker announced a tuck-in acquisition, saying it has agreed to acquire all of the assets in Synergetics USA's neurology portfolio, which achieved sales of $31 million in 2015. The move will give the company access to at least two electrosurgical devices that are currently distributed by rival Johnson & Johnson.

Smith & Nephew to sell OrthAlign precision alignment tech alongside its artificial knees

Usually in the news due to constant rumors of an impending takeover by Stryker, Smith & Nephew announced that it will distribute precision alignment surgery technology alongside its artificial knee implants under an agreement with Aliso Viejo, CA, startup OrthAlign.

Medtronic treats first patient with its investigational graft for aortic aneurysm repair

Medtronic signaled its interest in abdominal aortic aneurysm repair last year with the $110 million acquisition of Aptus Endosystems and investment in Arsenal AAA in return for an option to acquire the company. Now Medtronic says the first patient was treated in its trial of the Valiant TAAA Stent Graft System for thoracoabdominal aortic aneurysm.

As Zika fears spread, Cerus nabs American Red Cross partnership for blood pathogen reduction

More than a year after Cerus gained FDA approval--now the American Red Cross has bought into its technology with a multi-year deal for its Intercept Blood System for pathogen reduction in platelets and plasma. It's responsible for about 40% of the U.S. blood products, delivering 1.1 million plasma and 780,000 platelet units last year to almost 2,600 hospitals and transfusion centers.

Israeli upstart raises $15M for U.S. pivotal trial of bioresorbable cartilage implant

Regentis Biomaterials has raised a $15 million Series D round from investors led by Chinese biopharma Haisco Pharmaceutical Group. The Israeli cartilage repair company will use the financing to conduct a U.S. pivotal trial of its GelrinC, which is implanted as a liquid and forms into a resorbable implant that is ultimately replaced by newly regenerated cartilage.

MORE NEWS

From Our Sister Sites

FiercePharma

Mylan Chairman Robert Coury knows rejection but also the value of persistence. Four months after being spurned by Perrigo shareholders, he has a $7.2 billion deal to buy Sweden's Meda, a company that two years ago rejected an earlier Mylan proposal.

FiercePharma Manufacturing

Regulators in Spain are punishing a Barcelona-based drugmaker for a series of manufacturing shortfalls, recalling all batches produced by the company, Farma Mediterrania, from 2014 to present. The crackdown is the second in as many months by Spanish authorities on local producers.